ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Two-Week Break Balances RT Palliation, Side Effects

February 26, 2010

In Breif: Baltimore Developer Donates $10 Million To Univ. of Maryland Medical System

July 19, 1996

UT Board Announces Support for MD Anderson Tenure System

October 10, 2014

Cancer Groups Urge FDA To Spell Out Standards For Data Collection In Time-To-Progression Trials.

November 7, 2008

Chabner On Taxol, NSABP: “Makes You Lose Confidence In The Political Process”

May 12, 1995

In Brief: ACS Appoints Directors For Government Relations And Grassroots Development

April 25, 1997